Worth reading
63In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
0
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of the 27th Series Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment, mNAV, Minimum Exercise Price Adjustment and Exercise Suspension Clauses)
発行・処分する株式数0Shares
Shares delivered during the month: 0 shares
Intended allottee
EVO FUND (allottee of the stock acquisition rights)
発行済株式総数
Exercise ratio for the applicable month: —%. Exercise ratio subject to exercise restrictions: —%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
The exercise prices for the applicable month were ¥312, ¥326, ¥300, ¥279, ¥293, ¥271, ¥244, ¥251, ¥259, ¥249, ¥247, ¥251, ¥235, ¥238, ¥243, ¥288 and ¥293, respectively. An adjustment clause applies. The minimum exercise price is not disclosed.
Number of Stock Acquisition Rights
Total number issued: 1,000,000 rights. Unexercised balance as of the end of the month preceding the applicable month and at month-end: 947,300 rights.
Basis for determining the amount to be paid
Adjusted on each trading day to the closing price on the immediately preceding trading day, or to the minimum exercise price if that closing price is below the minimum exercise price. The initial adjustment was made on 17 April 2026. The discount and premium rates are not disclosed.
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise restrictions under Article 434 of the Listing Regulations. Whether an independent third-party opinion was obtained and shareholder approval was sought is not disclosed.
Most recent equity financing
Series 27 Stock Acquisition Rights issued on 1 April 2026. The issue price and funds raised are not disclosed.
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the 27th Series Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment, mNAV, Minimum Exercise Price Adjustment and Exercise Suspension Clauses) |
| Number of shares to be issued or disposed of | Shares delivered during the month: 0 shares |
| Intended allottee | EVO FUND (allottee of the stock acquisition rights) |
| Dilution Rate | Exercise ratio for the applicable month: —%. Exercise ratio subject to exercise restrictions: —% |
| Total number of issued shares | Not disclosed → 1,364,282,624 shares (as of 30 September 2026) |
| Basis for determining the amount to be paid | Adjusted on each trading day to the closing price on the immediately preceding trading day, or to the minimum exercise price if that closing price is below the minimum exercise price. The initial adjustment was made on 17 April 2026. The discount and premium rates are not disclosed. |
| Exercise price | The exercise prices for the applicable month were ¥312, ¥326, ¥300, ¥279, ¥293, ¥271, ¥244, ¥251, ¥259, ¥249, ¥247, ¥251, ¥235, ¥238, ¥243, ¥288 and ¥293, respectively. An adjustment clause applies. The minimum exercise price is not disclosed. |
| Number of Stock Acquisition Rights | Total number issued: 1,000,000 rights. Unexercised balance as of the end of the month preceding the applicable month and at month-end: 947,300 rights. |
| Procedures under the Corporate Code of Conduct | Describes compliance with the exercise restrictions under Article 434 of the Listing Regulations. Whether an independent third-party opinion was obtained and shareholder approval was sought is not disclosed. |
| Most recent equity financing | Series 27 Stock Acquisition Rights issued on 1 April 2026. The issue price and funds raised are not disclosed. |
Items this document does not state (18)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company is reporting the monthly exercise status for September 2026. In addition, 30 September 2026 was a record date or other reference date for determining shareholders, and the issuance terms stipulate that, under the procedures of the Japan Securities Depository Center, the exercise price is not adjusted on the day before or on the reference date.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.